Living Donor Liver Transplantation in Budd-Chiari Syndrome: A Single-Center Experience
Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.Transplantation Proceedings (Impact Factor: 0.98). 04/2010; 42(3):839-42. DOI: 10.1016/j.transproceed.2010.02.045
Budd-Chiari syndrome (BCS), which is characterized by hepatic venous outflow obstruction due to occlusion of the major hepatic vein and/or the inferior vena cava (IVC), is rare. Traditionally, a caval resection is advocated for these patients; however, such a maneuver renders living donor liver transplantation (LDLT) impossible. We encountered BCS in 4/377 LDLT patients during a 5-year period (January 2003 to December 2007). This report examine the various surgical modifications in these 4 patients, who underwent to LDLT for BCS. Resection of right hepatic vein (RHV) with an adjacent fibrotic part of the IVC with direct anastomosis of the graft RHV to the IVC was performed in 2 patients. One patient underwent retrohepatic IVC excision and reconstruction with a cryopreserved autologous IVC graft. The fourth patient, with a preexisting mesoatrial shunt for BCS, underwent conversion of this to a RHV atrial shunt. Graft and patient survivals were 100%. There were few complications in either donors or recipients. LDLT for BCS can be performed safely with adequate venous drainage techniques and with anticoagulant therapy and good follow-up for early diagnosis and treatment of recurrence leading to excellent long-term results.
Conference Paper: Similaritons: A new regime of femtosecond fiber lasers[Show abstract] [Hide abstract]
ABSTRACT: We have recently demonstrated theoretically that similaritons can exist in a laser oscillator. Initial attempts to observe and exploit the self-similar regime of operation produced excellent results. A Yb-doped fiber laser designed to approximate the similariton regime produces the parabolic chirped pulses and unique sharp-edged spectrum that are the signatures of self-similar propagation. Optimum performance was obtained by slightly deviating from the self-similar regime, and 50-fs pulses with 5-nJ energy were generated after dechirping. These results represent twice the pulse energy, twice the average power, 5 times the peak power of the previous best femtosecond fiber lasers. In addition, the laser is probably the most efficient femtosecond laser: 240 mW output power is obtained with 500 mW of pump power.Lasers and Electro-Optics Society, 2003. LEOS 2003. The 16th Annual Meeting of the IEEE; 11/2003
- [Show abstract] [Hide abstract]
ABSTRACT: Budd-Chiari syndrome (BCS) is a rare disease whose management should follow a step by step strategy. Anticoagulation and medical therapy should be the first line treatment. Revascularization or TIPS are indicated in case of no response to medical therapy. OLT should be indicated as a rescue therapy and anticoagulation be started soon after OLT. However, no clear indication can actually be given about the timing of different treatments. Moreover, there is some concern about treatment of some subgroup of patients, especially regarding the risk of recurrence after liver transplantation. The topic of this paper is to critically review the actual knowledge of BCS management.World Journal of Hepatology 10/2011; 3(10):262-4. DOI:10.4254/wjh.v3.i10.262
- [Show abstract] [Hide abstract]
ABSTRACT: Budd-Chiari syndrome is a rare but life-threatening disorder characterized by obstruction of the hepatic venous outflow. Treatment depends on the underlying cause, the location, and extent of the obstruction, and the functional capacity of the liver. A stepwise therapeutic approach is commonly accepted. When all other therapy options are unsuccessful, or in case of end-stage liver disease, transplant should be considered. We present case reports of 3 patients with Budd-Chiari syndrome who underwent living-donor liver transplant. Characteristic features of Budd-Chiari syndrome, diagnostic and therapeutic interventions, complications, and overall outcomes are discussed. We believe that when a deceased donor graft is unavailable, a living-donor liver transplant can be a safe option for patients with end-stage liver disease associated with Budd-Chiari syndrome.01/2012; 10(2):172-5. DOI:10.6002/ect.2011.0044
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.